시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 신장 판코니 증후군 시장 보고서(2025년)
Renal Fanconi Syndrome Global Market Report 2025
상품코드 : 1720878
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,265,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,056,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,846,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

신장 판코니 증후군 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 신장 증후군의 유병률 증가, 판코니-비켈 증후군 사례의 증가, 만성 신장병(CKD)의 유병률 증가, 연구개발 활동의 활성화, 임상시험의 급증에 기인한다고 생각됩니다.

신장 판코니 증후군의 유병률 상승이 신장 판코니 증후군 시장의 성장을 견인할 것으로 예측됩니다. 이 병태는 종종 신장 기능을 파괴하는 합병증을 일으키고 근위뇨관 장애의 위험을 높이고 진단 도구, 치료법 및 신장 판코니 증후군에 대한 높은 수요를 창출합니다. Research UK는 영국에서는 약 720만명이 만성 신장병을 앓고 있으며, 인구의 10% 이상을 차지하고 있다고 보고했습니다. 2033년까지는 환자 수가 761만 명으로 증가할 것으로 예측됩니다.

유전성 질환의 이환율 상승도 신장 판코니 증후군 시장의 성장을 가속할 것으로 예측됩니다. 유전자 검사의 동향, 의식의 향상, 환경의 영향, 유전성 질환 증가가 이 경향에 기여하고 있습니다. 신장 판코니 증후군의 많은 경우는 시스티노시스 및 윌슨병과 같은 유전성 질환과 관련이 있습니다. 이러한 유전성 질환의 유병률이 증가함에 따라 근위 요세관 기능 장애를 다루는 특수 진단 도구, 표적 요법 및 관리 전략에 대한 수요가 증가의 길을 따라 가면서 시장 확대를 더욱 촉진하고 있습니다. 예를 들어, 2024년 3월 미국을 기반으로 하는 국제기구인 유엔은 다운증이 세계 출생수의 약 1,000-1,100명에 1명의 비율로 발생하여, 이 염색체 장애를 가진 아이가 연간 3,000-5,000명 태어날 것으로 추정된다고 보고했습니다. 그 결과, 유전성 질환의 유병률 증가가 신장 판코니 증후군 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Renal Fanconi syndrome is a kidney disorder characterized by dysfunction in the proximal tubules, which play a crucial role in reabsorbing essential substances from urine into the bloodstream. This condition results in excessive urinary loss of vital nutrients such as glucose, amino acids, phosphate, bicarbonate, and potassium, despite their normal levels in the blood.

The primary types of Renal Fanconi syndrome are inherited (genetic) and acquired. Inherited Renal Fanconi syndrome is caused by genetic mutations that impair the kidney's ability to reabsorb essential nutrients, leading to imbalances in glucose, amino acids, phosphate, and bicarbonate. Treatment options include cystinosis treatment, symptomatic management, dietary modifications, antibiotics, kidney transplantation, and supplementation, administered through oral or intravenous routes. These treatments are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, serving end-users such as hospitals, specialty clinics, homecare settings, and others.

The renal fanconi syndrome market research report is one of a series of new reports from The Business Research Company that provides renal fanconi syndrome market statistics, including renal fanconi syndrome industry global market size, regional shares, competitors with a renal fanconi syndrome market share, detailed renal fanconi syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the renal fanconi syndrome industry. This renal fanconi syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The renal fanconi syndrome market size has grown steadily in recent years. It will grow from $0.53 billion in 2024 to $0.55 billion in 2025 at a compound annual growth rate (CAGR) of 4.0%. The growth during the historic period can be attributed to the high prevalence of blood disorders, an increased incidence of kidney diseases, the growing adoption of erythropoiesis-stimulating agents (ESAs), a rising elderly population, and the increasing prevalence of acute kidney injury (AKI).

The renal fanconi syndrome market size is expected to see steady growth in the next few years. It will grow to $0.63 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth during the forecast period can be attributed to the increasing prevalence of renal syndromes, a rise in cases of Fanconi-Bickel syndrome, the growing prevalence of chronic kidney disease (CKD), rising research and development activities, and a surge in clinical trials. Key trends expected during this period include advancements in innovative treatments, technological innovations, improvements in diagnostics, and the continuous development of advanced treatment options.

The rising prevalence of renal syndrome is expected to drive the growth of the renal Fanconi syndrome market. Renal syndromes encompass a group of kidney disorders that impair kidney function, leading to abnormalities in filtration, reabsorption, and electrolyte balance. Factors such as the increasing incidence of chronic kidney disease, aging populations, unhealthy lifestyles, and environmental influences contribute to the growing prevalence of renal syndromes. These conditions often lead to complications that disrupt kidney function, increasing the risk of proximal tubular dysfunction and creating a higher demand for diagnostic tools, treatments, and therapies for renal Fanconi syndrome. For example, in June 2023, Kidney Research UK, a UK-based non-profit organization, reported that approximately 7.2 million people in the UK live with chronic kidney disease, accounting for over 10% of the population. Of these, 3.25 million are in the advanced stages, while 3.9 million are in the early stages. By 2033, the number of affected individuals is expected to rise to 7.61 million. As a result, the increasing prevalence of renal syndrome is driving the growth of the renal Fanconi syndrome market.

The rising incidence of genetic disorders is also expected to fuel the growth of the renal Fanconi syndrome market. Advancements in genetic testing, greater awareness, environmental influences, and the increasing number of inherited conditions contribute to this trend. Many cases of Fanconi syndrome are associated with inherited genetic conditions such as cystinosis or Wilson's disease. As the prevalence of these genetic disorders rises, the demand for specialized diagnostic tools, targeted therapies, and management strategies to address proximal tubular dysfunction continues to grow, further driving market expansion. For instance, in March 2024, the United Nations, a US-based international organization, reported that Down syndrome occurs in approximately 1 in 1,000 to 1 in 1,100 live births worldwide, resulting in an estimated 3,000 to 5,000 children born with this chromosomal disorder annually. Consequently, the increasing prevalence of genetic disorders is contributing to the growth of the renal Fanconi syndrome market.

The growing development of personalized medicine is another factor propelling the growth of the renal Fanconi syndrome market. Personalized medicine tailors treatments and therapies based on an individual's genetic information, environment, and lifestyle, aiming for more precise and effective care. This approach is driven by advancements in genomic research, improved diagnostic technologies, and a better understanding of individual genetic variations. The increasing focus on personalized medicine enhances the effectiveness of treatments for renal Fanconi syndrome, fostering progress in diagnostic tools and targeted therapies. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the continued development of personalized medicine is accelerating the growth of the renal Fanconi syndrome market.

Major players in the renal fanconi syndrome market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi, Bristol-Myers Squibb, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Boehringer Ingelheim, Biogen Inc., Eisai Co. Ltd., Hikma Pharmaceuticals plc, Astellas Pharma Inc., Mallinckrodt Pharmaceuticals plc, CSL Vifor, Indivior plc, and Alnylam Pharmaceuticals Inc.

North America was the largest region in the renal fanconi syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in renal fanconi syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the renal fanconi syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The renal fanconi syndrome market consists of sales of diagnostic tests, treatment medications, and nutritional supplements designed to manage the condition. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Renal Fanconi Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on renal fanconi syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for renal fanconi syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renal fanconi syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Renal Fanconi Syndrome Market Characteristics

3. Renal Fanconi Syndrome Market Trends And Strategies

4. Renal Fanconi Syndrome Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Renal Fanconi Syndrome Growth Analysis And Strategic Analysis Framework

6. Renal Fanconi Syndrome Market Segmentation

7. Renal Fanconi Syndrome Market Regional And Country Analysis

8. Asia-Pacific Renal Fanconi Syndrome Market

9. China Renal Fanconi Syndrome Market

10. India Renal Fanconi Syndrome Market

11. Japan Renal Fanconi Syndrome Market

12. Australia Renal Fanconi Syndrome Market

13. Indonesia Renal Fanconi Syndrome Market

14. South Korea Renal Fanconi Syndrome Market

15. Western Europe Renal Fanconi Syndrome Market

16. UK Renal Fanconi Syndrome Market

17. Germany Renal Fanconi Syndrome Market

18. France Renal Fanconi Syndrome Market

19. Italy Renal Fanconi Syndrome Market

20. Spain Renal Fanconi Syndrome Market

21. Eastern Europe Renal Fanconi Syndrome Market

22. Russia Renal Fanconi Syndrome Market

23. North America Renal Fanconi Syndrome Market

24. USA Renal Fanconi Syndrome Market

25. Canada Renal Fanconi Syndrome Market

26. South America Renal Fanconi Syndrome Market

27. Brazil Renal Fanconi Syndrome Market

28. Middle East Renal Fanconi Syndrome Market

29. Africa Renal Fanconi Syndrome Market

30. Renal Fanconi Syndrome Market Competitive Landscape And Company Profiles

31. Renal Fanconi Syndrome Market Other Major And Innovative Companies

32. Global Renal Fanconi Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Renal Fanconi Syndrome Market

34. Recent Developments In The Renal Fanconi Syndrome Market

35. Renal Fanconi Syndrome Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기